
Thomas J Abbruscato

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1243672/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Role of Glucose Transporters in Brain Disease: Diabetes and Alzheimer's Disease. International Journal of Molecular Sciences, 2012, 13, 12629-12655.	4.1	204
2	Nicotine increases in vivo blood–brain barrier permeability and alters cerebral microvascular tight junction protein distribution. Brain Research, 2004, 1027, 48-58.	2.2	187
3	Nicotine and Cotinine Modulate Cerebral Microvascular Permeability and Protein Expression of ZO-1 through Nicotinic Acetylcholine Receptors Expressed on Brain Endothelial Cells. Journal of Pharmaceutical Sciences, 2002, 91, 2525-2538.	3.3	149
4	Blood-Brain Barrier Protection as a Therapeutic Strategy for Acute Ischemic Stroke. AAPS Journal, 2017, 19, 957-972.	4.4	130
5	Role of Nrf2 and protective effects of Metformin against tobacco smoke-induced cerebrovascular toxicity. Redox Biology, 2017, 12, 58-69.	9.0	116
6	A Functional Role for Sodium-Dependent Glucose Transport across the Blood-Brain Barrier during Oxygen Glucose Deprivation. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 487-495.	2.5	108
7	Protein expression of brain endothelial cell E-cadherin after hypoxia/aglycemia: influence of astrocyte contact. Brain Research, 1999, 842, 277-286.	2.2	94
8	Offsetting the impact of smoking and e-cigarette vaping on the cerebrovascular system and stroke injury: Is Metformin a viable countermeasure?. Redox Biology, 2017, 13, 353-362.	9.0	90
9	NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia. Neuroscience Letters, 2005, 383, 49-53.	2.1	75
10	Regulation of Blood-Brain Barrier Na,K,2Cl-Cotransporter through Phosphorylation during in Vitro Stroke Conditions and Nicotine Exposure. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 459-468.	2.5	72
11	Nicotine Exacerbates Brain Edema during In Vitro and In Vivo Focal Ischemic Conditions. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 371-379.	2.5	70
12	Opioid receptor agonists reduce brain edema in stroke. Brain Research, 2011, 1383, 307-316.	2.2	65
13	Transport of Opioid Peptides into the Central Nervous System. Journal of Pharmaceutical Sciences, 1998, 87, 1433-1439.	3.3	56
14	Brain and Spinal Cord Distribution of Biphalin: Correlation with Opioid Receptor Density and Mechanism of CNS Entry. Journal of Neurochemistry, 1997, 69, 1236-1245.	3.9	53
15	Neuroprotection in mice by NGP1-01 after transient focal brain ischemia. Brain Research, 2008, 1196, 113-120.	2.2	49
16	Nicotine and electronic cigarette (E ig) exposure decreases brain glucose utilization in ischemic stroke. Journal of Neurochemistry, 2018, 147, 204-221.	3.9	47
17	Evaluation of bEnd5 cell line as an in vitro model for the blood–brain barrier under normal and hypoxic/aglycemic conditions. Journal of Pharmaceutical Sciences, 2007, 96, 3196-3213.	3.3	46
18	Characterization of Neuroprotective Effects of Biphalin, an Opioid Receptor Agonist, in a Model of Focal Brain Ischemia. Journal of Pharmacology and Experimental Therapeutics, 2011, 339, 499-508.	2.5	42

#	Article	IF	CITATIONS
19	Tobacco Smoke Chemicals Attenuate Brain-to-Blood Potassium Transport Mediated by the Na,K,2Cl-Cotransporter during Hypoxia-Reoxygenation. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 248-254.	2.5	39
20	Functional upâ€regulation of endopeptidase neurolysin during postâ€acute and early recovery phases of experimental stroke in mouse brain. Journal of Neurochemistry, 2014, 129, 179-189.	3.9	38
21	DARK Classics in Chemical Neuroscience: Methamphetamine. ACS Chemical Neuroscience, 2018, 9, 2373-2378.	3.5	38
22	The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke. Current Pharmaceutical Design, 2014, 20, 1510-1522.	1.9	37
23	Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke. Life Sciences, 2021, 274, 119343.	4.3	33
24	Protein Kinase C Family Members as a Target for Regulation of Blood–Brain Barrier Na,K,2Cl-Cotransporter During In Vitro Stroke Conditions and Nicotine Exposure. Pharmaceutical Research, 2006, 23, 291-302.	3.5	32
25	In vitro and in vivo efficacy of a potent opioid receptor agonist, biphalin, compared to subtype-selective opioid receptor agonists for stroke treatment. Brain Research, 2015, 1609, 1-11.	2.2	32
26	Novel approaches for the delivery of therapeutics in ischemic stroke. Drug Discovery Today, 2020, 25, 535-551.	6.4	32
27	Nicotine pre-exposure reduces stroke-induced glucose transporter-1 activity at the blood–brain barrier in mice. Fluids and Barriers of the CNS, 2015, 12, 10.	5.0	27
28	Brain Delivery of a Potent Opioid Receptor Agonist, Biphalin during Ischemic Stroke: Role of Organic Anion Transporting Polypeptide (OATP). Pharmaceutics, 2019, 11, 467.	4.5	27
29	The Role of Smoking and Nicotine in the Transmission and Pathogenesis of COVID-19. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 498-509.	2.5	26
30	The neuroprotective role of the brain opioid system in stroke injury. Drug Discovery Today, 2018, 23, 1385-1395.	6.4	23
31	Peptidase neurolysin functions to preserve the brain after ischemic stroke in male mice. Journal of Neurochemistry, 2020, 153, 120-137.	3.9	22
32	Prenatal electronic cigarette exposure decreases brain glucose utilization and worsens outcome in offspring hypoxic–ischemic brain injury. Journal of Neurochemistry, 2020, 153, 63-79.	3.9	22
33	Preparation and preliminary characterization of recombinant neurolysin for in vivo studies. Journal of Biotechnology, 2016, 234, 105-115.	3.8	19
34	Neurovascular unit transport responses to ischemia and common coexisting conditions: smoking and diabetes. American Journal of Physiology - Cell Physiology, 2019, 316, C2-C15.	4.6	19
35	Enkephalin-Fentanyl Multifunctional Opioids as Potential Neuroprotectants for Ischemic Stroke Treatment. Current Pharmaceutical Design, 2017, 22, 6459-6468.	1.9	19
36	Potential role of myo-inositol to improve ischemic stroke outcome in diabetic mouse. Brain Research, 2018, 1699, 166-176.	2.2	17

#	Article	IF	CITATIONS
37	Estimating Brain Permeability Using In Vitro Blood-Brain Barrier Models. Methods in Molecular Biology, 2020, 2367, 47-72.	0.9	17
38	Biological determinants impact the neurovascular toxicity of nicotine and tobacco smoke: A pharmacokinetic and pharmacodynamics perspective. NeuroToxicology, 2022, 89, 140-160.	3.0	15
39	Drug Abuse and the Neurovascular Unit. Advances in Pharmacology, 2014, 71, 451-480.	2.0	13
40	Comparative assessment of in vitro BBB tight junction integrity following exposure to cigarette smoke and e-cigarette vapor: a quantitative evaluation of the protective effects of metformin using small-molecular-weight paracellular markers. Fluids and Barriers of the CNS, 2021, 18, 28.	5.0	13
41	Potential role of astrocyte angiotensin converting enzyme 2 in the neural transmission of COVID-19 and a neuroinflammatory state induced by smoking and vaping. Fluids and Barriers of the CNS, 2022, 19, .	5.0	13
42	In Vitro Models of the Blood–Brain Barrier. Methods in Molecular Biology, 2012, 814, 431-449.	0.9	12
43	Peptides at the blood brain barrier: Knowing me knowing you. Peptides, 2015, 72, 50-56.	2.4	10
44	Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability. Journal of Medicinal Chemistry, 2021, 64, 12705-12722.	6.4	10
45	Exosomes in Ischemic Stroke. Current Pharmaceutical Design, 2020, 26, 5533-5545.	1.9	10
46	Identification and Characterization of Two Structurally Related Dipeptides that Enhance Catalytic Efficiency of Neurolysin. Journal of Pharmacology and Experimental Therapeutics, 2021, 379, 191-202.	2.5	8
47	In-Vivo and Ex-Vivo Brain Uptake Studies of Peptidomimetic Neurolysin Activators in Healthy and Stroke Animals. Pharmaceutical Research, 2022, 39, 1587-1598.	3.5	6
48	Glutamate Buffering Capacity and Blood-Brain Barrier Protection of Opioid Receptor Agonists Biphalin and Nociceptin. Journal of Pharmacology and Experimental Therapeutics, 2021, 379, 260-269.	2.5	4
49	Effects of Nicotine Exposure From Tobacco Products and Electronic Cigarettes on the Pathogenesis of Neurological Diseases: Impact on CNS Drug Delivery. Frontiers in Drug Delivery, 2022, 2, .	1.6	3
50	Small molecule neurolysin activators, potential multi-mechanism agents for ischemic stroke therapy. Expert Opinion on Therapeutic Targets, 2022, 26, 401-404.	3.4	3
51	Structure-activity relationship studies of functionalized aromatic peptidomimetics as neurolysin activators. Bioorganic and Medicinal Chemistry Letters, 2022, 64, 128669.	2.2	2
52	Role of Myoâ€inositol in Ischemic Stroke Outcome in a Type 2 Diabetic Mouse Model. FASEB Journal, 2018, 32, .	0.5	1
53	Role of Sodium Glucose Transporter in High Glucose Mediated Angiotensin Type 1 receptor Downâ€regulation in Human Proximal Tubule Cells. FASEB Journal, 2008, 22, 736.1.	0.5	0
54	Upregulation of membraneâ€bound metalloendopeptidase neurolysin in a mouse model of focal brain ischemia. FASEB Journal, 2012, 26, 852.6.	0.5	0

#	Article	IF	CITATIONS
55	Role of Myo â€inositol in Ischemic Stroke Outcome in a Preclinical Tobacco Smoke Exposed Mouse Model. FASEB Journal, 2019, 33, 500.2.	0.5	0
56	Discovery of novel compound promotes neurogenesis by activation of mTOR signaling. FASEB Journal, 2020, 34, 1-1.	0.5	0
57	Prenatal Eâ€Cigarette Use Disrupts Bloodâ€Brain Barrier (BBB) Integrity and Induces Proâ€Inflammatory Cytokines in Postnatal Brain. FASEB Journal, 2022, 36, .	0.5	0